Skip to content

GBMM: A graph-based multimodal Mamba model for response prediction in patients with esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.

Sep 2026 · International Journal of Medical Informatics · Vol 222, pp. 106734 · 0 citations · 37 references
Medicine

Abstract

Objective

Neoadjuvant immunochemotherapy (NICT) can improve outcomes in advanced esophageal squamous cell carcinoma, but its efficacy varies significantly among patients. Accurately predicting response to NICT before treatment can help identify those who may benefit and avoid ineffective treatment. However, this remains challenging in clinical practice.

Methods

This study developed and validated a graph-based multimodal Mamba model (GBMM) for noninvasive prediction of treatment response using pretreatment CT imaging, radiomics features, and clinical variables. A total of 274 patients with esophageal squamous cell carcinoma who received NICT were enrolled retrospectively. The proposed GBMM integrated clinical features, radiomics features, deep image representations, and expert annotations through graph modeling, cross-modal interaction, Mamba-based representation learning, and teacher-student knowledge accrual. Model performance was evaluated in internal and external validation cohorts and compared with single-modality and conventional multimodal approaches.

Results

The model achieved area under the curve (AUC) values of 0.802 and 0.740 when evaluated on the internal and the external validation cohorts, respectively. These results were better than those of the state-of-the-art (SOTA) competing multimodal models. Decision curve analysis showed positive net benefit across a broad range of threshold probabilities. Shapley additive explanation (SHAP)-based interpretation highlighted tumor texture, morphology, systemic inflammatory status, physiological reserve, and regional disease burden as relevant predictive factors.

Conclusion

These findings suggest that GBMM may provide a useful framework for pretreatment prediction of NICT response in esophageal squamous cell carcinoma. Further validation on larger multicenter prospective cohorts is required before its potential clinical utility can be established.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.